Lung

14-3-3 theta, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including 14-3-3 theta.

Identifier RDF Subject URI of this object

QA State The current status with regard to quality assurance of this object.

Phase The current phase of the biomarker's development with regard to this organ.

Protocols Protocols (and studies) that are studying this object.

Publications Publications that have been written discussing this object.

Resources Additional resources about this object.

Datasets Datasets providing measured scientific bases for this biomarker.

Performance Comment A short summary of the biomarker performance with respect to a specific organ

Organ The organ for which the biomarker indicates diseases.

CLIA Certification

FDA Certification

Contents

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.